Literature DB >> 25621804

Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.

A Lawitschka1, M Faraci2, I Yaniv3, P Veys4, P Bader5, J Wachowiak6, G Socie7, M D Aljurf8, M Arat9, J J Boelens10, R Duarte11, A Tichelli12, C Peters1.   

Abstract

The aim of this analysis was to explore the diversity of reduced intensity conditioning (RIC) in paediatric allo-SCT in daily practice across Europe. Data from the European Group for Blood and Marrow Transplantation (EBMT) Promise database from 1994 to 2008 were supplemented by a survey of EBMT centres performing paediatric allo-SCT on the current policy asking for the underlying diseases and for the drug combinations. Records from 161 centres from 30 countries were analysed and 139 various RIC regimens were reported. More centres applied RIC for malignant rather than for non-malignant diseases. In general, fludarabine (FLU)-based regimens predominated except for BU-based regimens in myeloid malignancies and haemoglobinopathies. Treosulfan (TREO) was mainly applied for unspecified malignant diseases and for haemophagocytic diseases. FLU-based regimens revealed the greatest number of different combinations. Correlating the number of regimens with the number of treating centres revealed the lowest variety in FLU and the highest variety in TBI and TREO. FLU/melphalane and FLU/CY were the most frequent combinations. This extreme heterogeneity in RIC may influence both the efficacy and the safety of the procedures, which requires further investigation. Optimization and standardization of RIC is the final goal to provide a platform for future prospective studies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25621804     DOI: 10.1038/bmt.2014.306

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  26 in total

Review 1.  Hematopoietic stem cell transplants after reduced intensity conditioning regimen (RI-HSCT): report of a workshop of the European group for Blood and Marrow Transplantation (EBMT).

Authors:  A Bacigalupo
Journal:  Bone Marrow Transplant       Date:  2000-04       Impact factor: 5.483

2.  Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect.

Authors:  R Champlin; I Khouri; S Komblau; J Molidrem; S Giralt
Journal:  Oncology (Williston Park)       Date:  1999-05       Impact factor: 2.990

Review 3.  Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT).

Authors:  A Bacigalupo
Journal:  Bone Marrow Transplant       Date:  2002-02       Impact factor: 5.483

4.  A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients.

Authors:  G Del Toro; P Satwani; L Harrison; Y-K Cheung; M Brigid Bradley; D George; D J Yamashiro; J Garvin; D Skerrett; O Bessmertny; K Wolownik; C Wischhover; C van de Ven; M S Cairo
Journal:  Bone Marrow Transplant       Date:  2004-03       Impact factor: 5.483

5.  Relationship between mixed chimerism and rejection after bone marrow transplantation in thalassaemia.

Authors:  Marco Andreani; Manuela Testi; Mariarosa Battarra; Paola Indigeno; Annalisa Guagnano; Paola Polchi; Giorgio Federici; Guido Lucarelli
Journal:  Blood Transfus       Date:  2008-07       Impact factor: 3.443

Review 6.  Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases.

Authors:  P Satwani; N Cooper; K Rao; P Veys; P Amrolia
Journal:  Bone Marrow Transplant       Date:  2007-11-26       Impact factor: 5.483

7.  Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus.

Authors:  A Bacigalupo
Journal:  Bone Marrow Transplant       Date:  2004-04       Impact factor: 5.483

8.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

Authors:  Sergio Giralt; Karen Ballen; Douglas Rizzo; Andreas Bacigalupo; Mary Horowitz; Marcelo Pasquini; Brenda Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

9.  Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen.

Authors:  Kanchan Rao; Persis J Amrolia; Alison Jones; Catherine M Cale; Paru Naik; Doug King; Graham E Davies; H Bobby Gaspar; Paul A Veys
Journal:  Blood       Date:  2004-09-14       Impact factor: 22.113

10.  Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313.

Authors:  Michael A Pulsipher; Kenneth M Boucher; Donna Wall; Haydar Frangoul; Michel Duval; Rakesh K Goyal; Peter J Shaw; Ann E Haight; Michael Grimley; Stephan A Grupp; Morris Kletzel; Richard Kadota
Journal:  Blood       Date:  2009-06-15       Impact factor: 22.113

View more
  3 in total

1.  Fertility preservation issues in pediatric hematopoietic stem cell transplantation: practical approaches from the consensus of the Pediatric Diseases Working Party of the EBMT and the International BFM Study Group.

Authors:  A Balduzzi; J-H Dalle; K Jahnukainen; M von Wolff; G Lucchini; M Ifversen; K T Macklon; C Poirot; T Diesch; A Jarisch; D Bresters; I Yaniv; B Gibson; A M Willasch; R Fadini; L Ferrari; A Lawitschka; A Ahler; N Sänger; S Corbacioglu; M Ansari; R Moffat; A Dalissier; E Beohou; P Sedlacek; A Lankester; C D De Heredia Rubio; K Vettenranta; J Wachowiak; A Yesilipek; E Trigoso; T Klingebiel; C Peters; P Bader
Journal:  Bone Marrow Transplant       Date:  2017-07-24       Impact factor: 5.483

2.  Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.

Authors:  Eneida R Nemecek; Ralf A Hilger; Alexia Adams; Bronwen E Shaw; Deidre Kiefer; Jennifer Le-Rademacher; John E Levine; Gregory Yanik; Wing Leung; Julie-An Talano; Paul Haut; David Delgado; Neena Kapoor; Aleksandra Petrovic; Roberta Adams; Rabi Hanna; Hemalatha Rangarajan; Jignesh Dalal; Joseph Chewning; Michael R Verneris; Stacy Epstein; Lauri Burroughs; Evelio D Perez-Albuerne; Michael A Pulsipher; Colleen Delaney
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-09       Impact factor: 5.742

3.  Pediatric acute graft-versus-host disease prophylaxis and treatment: surveyed real-life approach reveals dissimilarities compared to published recommendations.

Authors:  Anita Lawitschka; Giovanna Lucchini; Brigitte Strahm; Jean-Hugues Dalle; Adriana Balduzzi; Brenda Gibson; Cristina Diaz De Heredia; Jacek Wachowiak; Arnaud Dalissier; Kim Vettenranta; Isaac Yaniv; Victoria Bordon; Dorothea Bauer; Peter Bader; Roland Meisel; Christina Peters; Selim Corbacioglu
Journal:  Transpl Int       Date:  2020-04-02       Impact factor: 3.782

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.